Vertex Pharmaceuticals Incorporated (VRTX)

NASDAQ: VRTX · Real-Time Price · USD

515.55

+9.80 (1.94%)

At close: Aug 17, 2026, 4:00 PM EDT

518.92

+3.37 (0.65%)

After-hours: Aug 17, 2026, 6:39 PM EDT

Vertex Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	4,405	3,953	-535.6	3,620	3,322	2,342
Depreciation & Amortization	190.9	178.6	182	169.5	148.3	125.6
Other Amortization	31.2	31.2	25.2	11.8	-	-
Asset Writedown & Restructuring Costs	-	379	-	-	-	-
Loss (Gain) From Sale of Investments	-	-	-	-	149.1	-17.1
Stock-Based Compensation	689.1	685.9	698.5	581.2	491.3	441.4
Other Operating Activities	-355	-397.4	-347.9	-579.1	-321.6	-143.3
Change in Accounts Receivable	-259.7	-347.3	-99.3	-84.1	-358.6	-274.7
Change in Inventory	-333.9	-524.2	-517.3	-322.9	-136.4	-92.8
Change in Accounts Payable	-28.1	36.8	49.5	48.7	120.8	31.9
Change in Other Net Operating Assets	-46.8	-364.4	52.3	92.6	715	230.4
Operating Cash Flow	4,293	3,631	-492.6	3,537	4,130	2,644
Operating Cash Flow Growth	11.61%	-	-	-14.35%	56.23%	-18.75%
Capital Expenditures	-496.8	-437.6	-297.7	-200.4	-204.7	-235
Cash Acquisitions	-	-	-	-	-295.9	-
Sale (Purchase) of Intangibles	-	-	-187.7	-58	-	-
Investment in Securities	-444.7	-483.1	-3,231	-2,852	227.3	-105.9
Other Investing Activities	58.7	-24.7	-54	-31	-47.8	-
Investing Cash Flow	-882.8	-945.4	-3,770	-3,142	-321.1	-340.9
Long-Term Debt Issued	-	-	-	-	-	28.3
Total Debt Issued	-	-	-	-	-	28.3
Long-Term Debt Repaid	-	-5.4	-33.6	-44.9	-85.5	-47
Total Debt Repaid	-5.4	-5.4	-33.6	-44.9	-85.5	-47
Net Debt Issued (Repaid)	-5.4	-5.4	-33.6	-44.9	-85.5	-18.7
Issuance of Common Stock	136.6	127.7	114.6	134.6	186.3	102
Repurchase of Common Stock	-2,332	-2,387	-1,582	-653.7	-172	-1,561
Other Financing Activities	3.8	3.7	6.2	1.8	3.5	-
Financing Cash Flow	-2,197	-2,261	-1,495	-562.2	-67.7	-1,478
Foreign Exchange Rate Adjustments	-40.8	90.9	-42.6	26.9	-29.2	-13.4
Net Cash Flow	1,172	515.6	-5,800	-139.7	3,712	811.2
Free Cash Flow	3,796	3,194	-790.3	3,337	3,925	2,409
Free Cash Flow Growth	8.47%	-	-	-14.99%	62.97%	-19.55%
Free Cash Flow Margin	30.16%	26.61%	-7.17%	33.81%	43.95%	31.80%
Free Cash Flow Per Share	14.81	12.38	-3.06	12.81	15.15	9.27
Levered Free Cash Flow	2,628	2,573	2,800	3,510	3,307	2,402
Unlevered Free Cash Flow	2,636	2,581	2,819	3,538	3,342	2,441
Cash Interest Paid	12.5	12.4	30.5	43.1	52.3	56.3
Cash Income Tax Paid	1,371	1,567	1,082	1,677	1,058	476.3
Change in Working Capital	-668.5	-1,199	-514.8	-265.7	340.8	-105.2

SEC Filings: 10-K · 10-Q